Coronavirus Notebook: Richer Countries Urged To Pay ‘Fair Share’ Of Vaccine & Drug Financing, EU Assesses Comirnaty Boosters
EFPIA has welcomed an evidence-based report on the regulatory flexibilities used in Europe during the pandemic and how they could be further employed in future. The EMA’s drug safety committee is looking at more reports of menstrual disorders with mRNA vaccines.
You may also be interested in...
With proposals for an overhaul of the EU medicines legislation due at the end of this year, EFPIA has published its formal response to the European Commission’s consultation with suggestions for facilitating new antibiotic development, testing new regulatory approaches to novel medicines, and tackling medicine shortages.
Coronavirus Notebook: Janssen Vaccine Effective Against Two Virus Variants In South Africa Study, But Gets EU Thrombocytopenia Warning
Data show that more than 480 million COVID-19 vaccines have now been administered in the EU/European Economic Area, with Malta, Iceland and Ireland leading the way in the percentage of people now fully vaccinated.
New supply arrangements with the two firms are expected to offer greater protection to people in Europe as the autumn/winter season approaches. The EU’s health crisis preparedness body HERA has also identified its “top three health threats.”